Literature DB >> 33077974

Latin America's embrace of an unproven COVID treatment is hindering drug trials.

Emiliano Rodríguez Mega.   

Abstract

Entities:  

Keywords:  Diseases; Government; Health care; Medical research; Public health; SARS-CoV-2

Mesh：

Substances：

Year:  2020        PMID： 33077974     DOI： 10.1038/d41586-020-02958-2

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  3 in total

1.  The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.

Authors:  Leon Caly; Julian D Druce; Mike G Catton; David A Jans; Kylie M Wagstaff
Journal:  Antiviral Res       Date:  2020-04-03       Impact factor: 5.970

2.  Serious Neurological Adverse Events after Ivermectin-Do They Occur beyond the Indication of Onchocerciasis?

Authors:  Rebecca E Chandler
Journal:  Am J Trop Med Hyg       Date:  2017-11-30       Impact factor: 2.345

3.  Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19.

Authors:  Ricardo Peña-Silva; Stephen B Duffull; Andrew C Steer; Sandra X Jaramillo-Rincon; Amanda Gwee; Xiao Zhu
Journal:  Br J Clin Pharmacol       Date:  2020-07-17       Impact factor: 3.716
  3 in total
  19 in total

Review 1.  Ivermectin for preventing and treating COVID-19.

Authors:  Maria Popp; Stefanie Reis; Selina Schießer; Renate Ilona Hausinger; Miriam Stegemann; Maria-Inti Metzendorf; Peter Kranke; Patrick Meybohm; Nicole Skoetz; Stephanie Weibel
Journal:  Cochrane Database Syst Rev       Date:  2022-06-21

2.  Saving millions of lives but some resources squandered: emerging lessons from health research system pandemic achievements and challenges.

Authors:  Stephen R Hanney; Sharon E Straus; Bev J Holmes
Journal:  Health Res Policy Syst       Date:  2022-09-10

3.  Coronavirus 2019 Infectious Disease Epidemic: Where We Are, What Can Be Done and Hope For.

Authors:  Michele Carbone; John Lednicky; Shu-Yuan Xiao; Mario Venditti; Enrico Bucci
Journal:  J Thorac Oncol       Date:  2021-01-07       Impact factor: 15.609

4.  Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment.

Authors:  Miguel Angel Martinez
Journal:  Front Immunol       Date:  2021-03-11       Impact factor: 7.561

5.  Standard Dose Ivermectin for COVID-19.

Authors:  Dora Buonfrate; Zeno Bisoffi
Journal:  Chest       Date:  2021-05       Impact factor: 9.410

6.  High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial.

Authors:  Dora Buonfrate; Fabio Chesini; Davide Martini; Maria Carla Roncaglioni; Maria Luisa Ojeda Fernandez; Maria Francesca Alvisi; Irene De Simone; Eliana Rulli; Alessandro Nobili; Giacomo Casalini; Spinello Antinori; Marco Gobbi; Caterina Campoli; Michela Deiana; Elena Pomari; Gianluigi Lunardi; Roberto Tessari; Zeno Bisoffi
Journal:  Int J Antimicrob Agents       Date:  2022-01-06       Impact factor: 5.283

Review 7.  Therapeutics for COVID-19 and post COVID-19 complications: An update.

Authors:  Debdoot Basu; Vivek P Chavda; Anita A Mehta
Journal:  Curr Res Pharmacol Drug Discov       Date:  2022-02-04

8.  Ivermectin for preventing and treating COVID-19.

Authors:  Maria Popp; Miriam Stegemann; Maria-Inti Metzendorf; Susan Gould; Peter Kranke; Patrick Meybohm; Nicole Skoetz; Stephanie Weibel
Journal:  Cochrane Database Syst Rev       Date:  2021-07-28

9.  How a few poorly designed COVID-19 studies may have contributed to misinformation in Brazil: the case for evidence-based communication of science.

Authors:  Charles Phiilipe de Lucena Alves; João de Deus Barreto Segundo; Gabriel Gonçalves da Costa; Tatiana Pereira-Cenci; Kenio Costa Lima; Flávio Fernando Demarco; Inácio Crochemore-Silva
Journal:  BMJ Open Sci       Date:  2021-09-02

10.  Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial.

Authors:  Julio Vallejos; Rodrigo Zoni; María Bangher; Silvina Villamandos; Angelina Bobadilla; Fabian Plano; Claudia Campias; Evangelina Chaparro Campias; Maria Fernanda Medina; Fernando Achinelli; Hector Andres Guglielmone; Jorge Ojeda; Diego Farizano Salazar; Gerardo Andino; Pablo Kawerin; Silvana Dellamea; Antonia Cristina Aquino; Victor Flores; Carolina N Martemucci; Silvina Maria Martinez; Juan Emanuel Segovia; Paola Itati Reynoso; Noelia Carolina Sosa; Mariana Elizabeth Robledo; Joaquina Maria Guarrochena; Maria Mercedes Vernengo; Natalia Ruiz Diaz; Elba Meza; María Gabriela Aguirre
Journal:  BMC Infect Dis       Date:  2021-07-02       Impact factor: 3.090
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.